Overview

Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects

Status:
Completed
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy male participants aged 18 to 45 years.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi
Treatments:
Gemfibrozil
Rifampin